Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOB | P04114 | 10/20 | 0.45 |
| ▸ | MTTP | P55157 | 10/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 3/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6199303 | 1.00 | APOB (0.45) | APOBMTTPCA1CA2CA12 | |
| SCHEMBL1545211 | 0.87 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL29878515 | 0.87 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1545004 | 0.87 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL1545000 | 0.87 | EPHX2 (0.50) | CA1CA2CA12CA7CA14 | |
| SCHEMBL4808483 | 0.84 | CA1 (0.61) | APOBMTTPCA1CA2CA12 | |
| SCHEMBL1590871 | 0.82 | CA1 (0.44) | CA1CA2CA12CA7CA14 | |
| SCHEMBL17478439 | 0.81 | MALT1 (0.51) | MALT1MTNR1A | |
| SCHEMBL17478440 | 0.81 | MALT1 (0.51) | MALT1MTNR1A | |
| SCHEMBL8765995 | 0.81 | MTNR1A (0.62) | APOBMTTPCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1259484-B1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2005-05-18 | — | — | EP | disclosed |
| US-6878707-B2 | Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | NOVARTIS AG (CH) | 2003-06-12 | — | — | US | disclosed |
| EP-1259484-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | Novartis AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001053260-A1 | CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| US-6197798-B1 | INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN | NOVARTIS AG (CH) | 2001-03-06 | — | — | US | disclosed |
| WO-2001005767-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109700-A1 | Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion | APOB, CETP, MTTP | APOB 1/4885MTTP 3/4885CA1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.